Myeloid-Derived Suppressor Cells Recruited by Chemokine (C-C Motif) Ligand 3 Promote the Progression of Breast Cancer via Phosphoinositide 3-Kinase-Protein Kinase B-Mammalian Target of Rapamycin Signaling.
Breast neoplasms
Chemokine CCL3
Epithelial-mesenchymal transition
Myeloid-derived suppressor cells
Tumor microenvironment
Journal
Journal of breast cancer
ISSN: 1738-6756
Titre abrégé: J Breast Cancer
Pays: Korea (South)
ID NLM: 101314183
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
11
09
2019
accepted:
05
04
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
13
5
2020
Statut:
ppublish
Résumé
Numerous studies have shown that the frequency of myeloid-derived suppressor cells (MDSCs) is associated with tumor progression, metastasis, and recurrence. Chemokine (C-C motif) ligand 3 (CCL3) may be secreted by tumor cells and attract MDSCs into the tumor microenvironment. In the present study, we aimed to explore the molecular mechanisms whereby CCL3 is involved in the interaction of breast cancer cells and MDSCs. The expression of CCL3 and its receptors was investigated using real-time polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assay. The cell counting Kit-8, wound healing, and transwell assays were performed to study cell growth, migration, and invasion. Cell cycling, apoptosis, and the frequency of MDSCs were investigated through flow cytometry. Transwell assays were used for co-culture and chemotaxis detection. Markers of the epithelial-mesenchymal transition (EMT) were determined with western blotting. The role of CCL3 CCL3 promoted cell proliferation, migration, invasion, and cycling, and inhibited apoptosis of breast cancer cells CCL3 promoted the growth of breast cancer cells, and MDSCs recruited by CCL3 interacted with these cells and then activated the PI3K-Akt-mTOR pathway, which led to EMT and promoted the migration and invasion of the cells.
Identifiants
pubmed: 32395374
doi: 10.4048/jbc.2020.23.e26
pmc: PMC7192746
doi:
Types de publication
Journal Article
Langues
eng
Pagination
141-161Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Korean Breast Cancer Society.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declare that they have no competing interests.
Références
PLoS One. 2015 May 20;10(5):e0127028
pubmed: 25992611
Int J Cancer. 2013 Dec 15;133(12):2872-83
pubmed: 23737434
Cancer Treat Rev. 2016 Apr;45:87-96
pubmed: 26995633
Mediators Inflamm. 2015;2015:159269
pubmed: 26078490
PLoS Biol. 2011 Sep;9(9):e1001162
pubmed: 21980263
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
Cancer Res. 2012 Mar 15;72(6):1384-94
pubmed: 22282653
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
pubmed: 17210725
Nat Commun. 2017 Apr 06;8:14979
pubmed: 28382931
Cancer Cell. 2008 Jan;13(1):23-35
pubmed: 18167337
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30
pubmed: 21644036
Leukemia. 2011 Jul;25(7):1174-81
pubmed: 21403648
Cell Rep. 2017 Nov 21;21(8):2212-2222
pubmed: 29166611
Oncotarget. 2016 Sep 27;7(39):64505-64511
pubmed: 27542274
Cancer Metastasis Rev. 2016 Dec;35(4):515-524
pubmed: 27896521
Front Biosci. 2008 May 01;13:6820-33
pubmed: 18508696
Curr Pharm Des. 2015;21(10):1301-10
pubmed: 25506895
J Cell Physiol. 2018 Apr;233(4):3024-3036
pubmed: 28661031
Cancer Immunol Immunother. 2014 May;63(5):513-28
pubmed: 24652403
Immunity. 2008 Oct 17;29(4):565-77
pubmed: 18848473
Biochim Biophys Acta. 2014 Aug;1846(1):55-65
pubmed: 24727385
J Transl Med. 2015 Feb 01;13:47
pubmed: 25638150
Nature. 2013 Feb 7;494(7435):133-6
pubmed: 23389545
Sci Signal. 2016 Jun 28;9(434):fs13
pubmed: 27353363
Cell Commun Signal. 2013 Sep 18;11:68
pubmed: 24047437
Cancer Immunol Res. 2016 Feb;4(2):101-12
pubmed: 26603621
J Immunol. 2008 Nov 1;181(9):6384-93
pubmed: 18941229